MRX, Medicis Pharmaceutical Corp.
Medicis Pharmaceutical Corporation (NYSE:MRX) engages in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States, Canada, and Europe.
MRX is dedicated to helping patients attain a healthy and youthful appearance and self-image. MRX's products address various conditions or aesthetic improvements, including facial wrinkles, glabellar lines, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, seborrheic dermatitis, and cosmesis.
MRX's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.
Recently, MRX reported its Fourth Quarter and Year-End 2010 Results
Previously, MRX and Anacor Pharmaceuticals, Inc. announced that the two companies have entered into a research and development agreement to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne.
Read more at: http://crwewallstreet.com/?p=16125